In fact, the FDA approved HER2 targeted ADC, Enhertu, has shown efficacy in the metastatic HER2-low breast cancer subtype (indication revised in August 2022) clearly suggesting a need for biomarkers other than the target antigen. The gene discussed is ERBB2; the disease is breast cancer.